Search Within

Advanced Practice Providers

  1. "Molecular Imaging and Therapy Service"
Formats
  1. Meeting Abstract (51)
  2. Journal Article (27)
Groups
  1. Molecular Imaging and Therapy Service (78)
  2. Radiology, Department of (77)
  3. Nursing (56)
  4. Survivorship Research (53)
  5. Center for Hematologic Malignancies (48)
  6. Department of Medicine (46)

More Groups

People
  1. Heiko Schoder (31)
  2. Kim Kramer (28)
  3. Neeta Pandit-Taskar (28)
  4. Alison Moskowitz (26)
  5. Andrew Zelenetz (26)
  6. Ariela Noy (26)

More People

Years
  1. 2025 (1)
  2. 2024 (5)
  3. 2023 (3)
  4. 2022 (6)
  5. 2021 (10)
  6. 2020 (5)

More Years

Publications
  1. Blood (21)
  2. Journal of Clinical Oncology (13)
  3. Neuro-Oncology (10)
  4. Pediatric Blood and Cancer (6)
  5. Hematological Oncology (4)
  6. Journal of Nuclear Medicine (3)

More Publications

Publishers
  1. American Society of Hematology (21)
  2. American Society of Clinical Oncology (13)
  3. Oxford University Press (12)
  4. Wiley Blackwell (6)
  5. Wiley Periodicals, Inc (6)
  6. Elsevier Inc. (4)

More Publishers

Results (78)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Chimeric antigen receptor (CAR(+)) modified T cells targeting prostate-specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC)
    Meeting Abstract

    Slovin, S. F.; Wang, X.; Hullings, M.; Arauz, G.; Bartido, S.; Lewis, J. S.; Schoder, H.; Zanzonico, P.; Scher, H. I.; Sadelain, M.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Chimeric antigen receptor (CAR(+)) modified T cells targeting prostate specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC)
    Meeting Abstract

    Slovin, S. F.; Wang, X.; Hullings, M.; Arauz, G.; Bartido, S.; Lewis, J. S.; Schoder, H.; Zanzonico, P.; Scher, H. I.; Riviere, I.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • FDG-PET adapted sequential therapy with brentuximab vedotin and augmented ICE followed by autologous stem cell transplant for relapsed and refractory Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A.; Schoder, H.; Gerecitano, J. F.; Hamlin, P.; Horwitz, S. M.; Matasar, M. J.; Keskinyan, V. S.; McCall, S.; Noy, A.; Palomba, M. L.; more...
    Blood (2013)

    Fulltext@MSK | Save
  • A phase I study of the androgen signaling inhibitor ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Rathkopf, D. E.; Morris, M. J.; Danila, D. C.; Slovin, S. F.; Steinbrecher, J. E.; Arauz, G.; Curley, T.; Rix, P. J.; Maneval, E. C.; Chen, I.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Phase I/II safety and pharmacokinetic (PK) study of ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase I results of a Prostate Cancer Clinical Trials Consortium study
    Meeting Abstract

    Rathkopf, D. E.; Danila, D. C.; Morris, M. J.; Slovin, S. F.; Steinbrecher, J. E.; Arauz, G.; Rix, P. J.; Maneval, E. C.; Chen, I.; Fox, J. J.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody cixutumumab (cix) plus mTOR inhibitor temsirolimus (tem) in metastatic castration-resistant prostate cancer (mCRPC): Results of a phase I pilot study
    Meeting Abstract

    Rathkopf, D. E.; Danila, D. C.; Morris, M. J.; Slovin, S. F.; Borwick, L. S.; Momen, L.; Curley, T.; Arauz, G.; Larson, S. M.; Fleisher, M.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Risk-adapted therapy using biopsy confirmation of abnormal interim FDG-PET for patients with advanced stage diffuse large B cell lymphoma (DLBCL), and exploratory evaluation of FLT-PET
    Meeting Abstract

    Moskowitz, C. H.; Schoder, H.; Hamlin, P. A.; Gerecitano, J. F.; Horwitz, S. M.; Matasar, M. J.; Moskowitz, A. J.; Noy, A.; Palomba, M.; Portlock, C. S.; more...
    Annals of Oncology (2011)

    Fulltext@MSK | Save
  • N7: A novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age
    Journal Article

    Cheung, N. K. V.; Kushner, B. H.; Laquaglia, M.; Kramer, K.; Gollamudi, S.; Heller, G.; Gerald, W.; Yeh, S.; Finn, R.; Larson, S. M.; more...
    Medical and Pediatric Oncology (2001)

    Fulltext@MSK | Save